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Type 1 diabetes mellitus (T1DM) has been associated to several cartilage and bone alterations including growth 2 
retardation, increased fracture risk and bone loss. To determine the effect of long term diabetes on bone we used 3 
adult and aging Ins2
Akita
 mice that developed T1DM around 3-4 weeks after birth. Both Ins2
Akita
 and WT mice 4 
were analyzed at 4, 6 and 12 months to assess bone parameters such as femur length, growth plate thickness and 5 
number of mature and pre-apoptotic chondrocytes. In addition, bone microarchitecture of the cortical and 6 
trabecular regions was measured by microCT and gene expression of Adamst-5, Col2, Igf1, Runx2, Acp5 and Oc 7 
was quantified by qRT-PCR. Ins2
Akita
 mice showed a decreased longitudinal growth of the femur that was related 8 
to decreased growth plate thickness, lower number of chondrocytes and to a higher number of pre-apoptotic 9 
cells. These changes were associated with higher expression of Adamst-5, suggesting higher cartilage 10 
degradation, and with low expression levels of Igf1 and Col2 that reflect the decreased growth ability of diabetic 11 
mice. Ins2
Akita
 bone morphology was characterized by low cortical bone area (Ct.Ar) but higher trabecular bone 12 
volume (BV/TV) and expression analysis showed a downregulation of bone markers Acp5, Oc and Runx2. 13 
Serum levels of insulin and leptin were found to be reduced at all time points Ins2
Akita
. We suggest that Ins2
Akita
 14 
mice bone phenotype is caused by lower bone formation and even lower bone resorption due to insulin 15 
deficiency and to a possible relation with low leptin signaling. 16 












The global prevalence of type 1 diabetes mellitus (T1DM) has been increasing at a rate of 2-5% a year (Maahs, 2 
West, Lawrence, & Mayer-Davis, 2010) leading to an increase in diabetes related pathologies, including bone 3 
disorders. T1DM was previously shown to induce alterations in cartilage (Coe, Zhang, & McCabe, 2012) and 4 
bone loss (Coe et al., 2012; K. J. Motyl et al., 2009), associated to different factors like higher glucose serum 5 
concentration and lower insulin secretion by the β-cells, inflammation and altered gene expression. Advanced 6 
glycation end products (AGEs) are proteins or lipids that are formed in hyperglycemic environments. Since their 7 
cumulative effects increase with age, they represent a key player in vascular disease associated to diabetes 8 
(Goldin, Beckman, Schmidt, & Creager, 2006). AGEs are involved in an increase in inflammatory activity and a 9 
decrease in bone formation due to osteoblastic apoptosis and decreased osteoblast proliferation (Gangoiti, 10 
Anbinder, Cortizo, & McCarthy, 2013) or higher osteoclastic activation (Sanguineti, Puddu, Mach, Montecucco, 11 
& Viviani, 2014), as well as chondrocyte apoptosis in cartilage (Tsai et al., 2013). The receptor for AGEs 12 
(RAGE) is assumed to be the molecular intervenient that activates the pathways leading to oxidative stress and 13 
inflammation (Ramasamy, Yan, & Schmidt, 2012) including in bone since osteoblasts, osteoclasts and 14 
chondrocytes express RAGE (Mercer, Ahmed, Etcheverry, Vasta, & Cortizo, 2007; Nah et al., 2007). 15 
Hypoinsulinemia present in T1DM can also affect bone metabolism, since insulin signaling in osteoblasts was 16 
found to regulate bone resorption by activating osteoclastic activity (Ferron, Wei, & Yoshizawa, 2010), releasing 17 
undercarboxylated osteocalcin to the blood stream, which in turn affects glucose homeostasis by signaling 18 
insulin secretion in β-cells and other insulin sensitive tissues (Lee et al., 2007). This relationship between bone 19 
and insulin was demonstrated when Ob-IR mice, lacking the insulin receptor (IR) only in osteoblasts, became 20 
glucose intolerant (Ferron et al., 2010). Both T1DM patients and mice models face a rapid weight loss during the 21 
onset of the disease (Coe et al. 2012; Motyl and McCabe 2009), that persists if not treated, creating a state 22 
resembling an accelerated fast that results in loss of fat and proteins. Weight loss has been associated with low 23 
bone mass (M W Hamrick & Ferrari, 2008), but interestingly only a decrease in levels of fat mass were found to 24 
be correlated with decreased bone mineral density (BMD) and not lean mass or total body weight (Fogelholm, 25 
Sievänen, Kukkonen-Harjula, & Pasanen, 2001). This close relationship between fat and bone seems to be 26 
explained by the fact that adipocytes secrete leptin. Accordingly, both the ob/ob leptin and the db/db leptin 27 
receptor mutant mice have impaired bone formation, exhibiting a normal or decreased cortical bone volume 28 
(BV/TV) although presenting a higher trabecular bone volume (BV/TV) (Ducy et al., 2000; Turner et al., 2013). 29 
It was postulated that leptin binding to its receptors in the hypothalamus increases the expression of 30 
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noradrenaline activating β2-adrenergic receptors pathway in osteoblasts, inhibiting bone formation and 1 
increasing the expression of RANKL, promoting the differentiation and proliferation of osteoclasts (Ducy et al., 2 
2000; Elefteriou et al., 2005). These findings were supported by the results of β2-adrenergic receptor KO mice 3 
(Adrb2
-/-
), that exhibit an increase in trabecular bone at the age of 6 months (Elefteriou et al., 2005). It has been 4 
proposed that peripherally, leptin promotes osteoblast proliferation through leptin receptor signaling (Cornish et 5 
al., 2002) and more recently, Turner and colleagues (Turner et al., 2013) proposed that peripheral leptin induces 6 
bone formation and resorption, this representing the main route of action of leptin in bone. Food intake is 7 
correlated with high levels of leptin and fasting periods are associated with low levels of leptin, as previously 8 
observed in fasting mice and in anorexia nervosa (Devlin et al., 2010; Soyka, Grinspoon, Levitsky, Herzog, & 9 
Klibanski, 1999). Devlin et al. (2010) in their experiments with mice under caloric restriction (CR), from 3 to 12 10 
weeks of age, not only correlated leptin levels with CR but also with low cancellous BV/TV and low cortical 11 
area, assuming that CR in juvenile mice under a fast period of growth lead to bone loss. But unexpected results 12 
were observed in 6 months mice after a period of 10 weeks under CR (Mark W Hamrick, Ding, Ponnala, Ferrari, 13 
& Isales, 2008), which presented low cortical mass, but higher trabecular BV/TV in the vertebra and unchanged 14 
trabecular BV/TV in the femur. In our study we hypothesize that inflammation, together with insulin deficiency 15 
and a possible decrease in leptin signaling, could be the principal causes involved in the cartilage and bone 16 
phenotypes observed in Ins2
Akita
.  17 
Materials and Methods 18 
Mouse models 19 
Five male wild type (WT) C57BL/6 and five male heterozygous Ins2
Akita
 (C57BL/6 background) were sampled 36 
at each of the stages analyzed, 4, 6 and 12 months of age (total of 30 mice) and were used to perform the 37 
experimental procedures. Diabetes was monitored by blood glucose measurements using a Glucose Assay Kit 38 
(Free Style Precision, Abbott Laboratories, Illinois, USA) and only Ins2
Akita
 mice with glucose values >300 39 
mg/dl were used in this experiment. All animal manipulations were conducted in accordance with principles and 40 
procedures following the guidelines from the Federation of Laboratory Animal Science Associations (FELASA). 41 
Mutant and wildtype mice were originally purchased from Jackson Laboratory (Bar Harbor, Maine) and colonies 42 
established in the local bioterium at the University of Algarve. All animals were kept on a light/dark (12h/12h) 43 
cycle at 23ºC, and received food (standard lab chow) and water ad libitum. 44 
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Total RNA isolation  1 
Left femur and tibia were isolated and cleaned from adhering tissues, the bone marrow was flushed out with PBS 2 
and the bone was snap‐frozen in liquid nitrogen. Frozen bones were crushed using a mortar and pestle under 3 
liquid nitrogen and RNA extracted with the Isol-RNA Lysis Reagent 5 PRIME® (Hilden, Deutschland) 4 
according to manufacturer’s protocol. RNA integrity was verified using Experion
TM
 RNA Analysis Kit (BIO-5 
RAD, Hercules, CA, USA).  6 
Quantitative real‐time polymerase chain reaction (qRT-PCR) 7 
Reverse transcription was performed using Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV 8 
RT) (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. qRT‐PCR was 9 
performed using the iQ™ SYBR
®
 Green Supermix (Life Technologies) and specific primers on an CFX96 10 
Touch™ Real-Time PCR Detection System (BIO-RAD, Hercules, CA, USA) for 40 cycles, each with 15 sec. for 11 
annealing and 30 sec. for amplification, followed by a melt curve analysis, as described (Technologies, 2011). 12 
All gene expression data were normalized against hypoxanthine phosphoribosyltransferase 1 (Hrpt1), and 13 
relative quantification calculated according to the 2
-∆∆Ct
 method as previously described (Pfaffl, 2004). Primers 14 
used for Disintegrin and metalloproteinase with thrombospondin motifs 5 (Adamst-5), Collagen Type II (Col2), 15 
Insulin-like growth factor 1 (Igf1), Runt-related transcription factor 2 (Runx2), Osteocalcin (Oc) and  Tartrate 16 
resistant acid phosphatase (Acp5) amplification are available in supplementary material.    17 
 18 
Serum measurements 19 
Blood serum from three WT and Ins2
Akita
 at 4, 6 and 12 months was collected and stored at −80°C. Leptin was 20 
measured using a Life technologies Novex Mouse Leptin ELISA Kit (Frederick, MD, USA) according to the 21 
manufacturer’s protocol. Insulin was measured using a Demeditec Insulin rat ELISA kit (Kiel, Germany) 22 
according to the manufacturer’s protocol. 23 
 24 
Bone histology and histomorphometry 25 
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The right tibias were fixed in 4% paraformaldehyde, (pH 7.4 in PBS), and decalcified in 10% EDTA/TRIS-HCl 1 
(pH 7.4) for 15 days, then transferred to 70% Ethanol and processed for dehydration and infiltration on a routine 2 
overnight processing schedule. For histomorphometry 5 animals per group were used and 4 sections were 3 
analyzed in each of the cortical proximal, mid shaft and distal regions per tibia. Samples were embedded in 4 
paraffin and sagittal sections with 6 µm prepared in a microtome (Microm HM340E, Germany). Before staining, 5 
sections were deparaffinized in xylene and dehydrated in an increasing gradient of ethanol. Sections were stained 6 
with safranin O, fast green and Mayer´s hematoxylin (Glasson, Chambers, Van Den Berg, & Little, 2010) and 7 
photographed, at a magnification of 100x, under a Zeiss microscope equipped with a PowerShot G12 camera 8 
(Canon, Tokyo, Japan) and a LA-DC58K conversion lens adapter (Zeiss, Oberkochen, Germany). All 9 
histomorphometric analysis were conducted under blind evaluation by giving a code to each captured image. 10 
Growth plate measurements  11 
For assessment of the growth plate (GP) thickness, 8 to 10 measurements were performed, separated by 0.05 mm 12 
of distance, for each GP sample. 5 animals for each group were used and 3 histological sections separated by 25 13 
µm per tibia were analyzed. Morphological criteria, for growth plate measurements, was defined by the region 14 
stained with Safranin O (cartilaginous tissue) and measurements were performed longitudinally.  Proliferative 15 
chondrocytes were identified according to its morphology and position in the growth plate. 16 
Immunohistochemistry  17 
Sections were processed as described above. After deparaffinization and hydration, heat mediated epitope 18 
retrieval was performed for 25 min in tris-EDTA pH9 buffer and hyaluronidase (Sigma H3506) treatment for 30 19 
min. Sections were incubated for 30 min. with blocking buffer (Goat serum and BSA) to block unspecific 20 
binding sites and then incubated overnight at 4 °C with rabbit polyclonal Anti-Caspase-3 diluted in PBS 1:100 21 
(ab13847, ABCAM, Cambridge, UK). Slides were then incubated in 0.3% H2O2 in PBS with 0.1% Triton X-100 22 
for 15 min. The secondary antibody, anti-rabbit IgG – peroxidase (Sigma Aldrich) was applied diluted 1:100 in 23 
PBS and incubated for 90 min at room temperature. The signal was detected by incubating the sections for 4 min 24 
in a 0.1% 3,3′-diaminobenzidine (DAB) substrate and 0.02% hydrogen peroxide solution. The sections were 25 
counterstained with Mayer’s hematoxylin.  26 
Detection of apoptosis 27 
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Total numbers of Caspase 3 positive proliferative and hypertrophic cells were counted and hematoxylin stained 1 
cells were used as negative control for pre-apoptotic cells. From each animal tested, at least 3 sections from each 2 
tibia, separated by 25 µm, were observed and the percentage of apoptotic cells in growth plate determined. Cells 3 
were counted using the cell counter plug-in for the imageJ software. 4 
Osteoclast evaluation  5 
For osteoclast evaluation 3 undecalcified fixed femurs per group were embedded in methacrylate and sectioned 6 
into sagittal sections with a thickness of 5 µm. Each slide was stained (3 per femur) for tartrate-resistant acid 7 
phosphatase (ACP5) using naphthol AS-TR phosphate and hexazotized pararosaniline (Sigma Aldrich, St. Louis, 8 
USA) and counterstained with methyl green. Histomorphometric evaluation was performed from captured 9 
micrographs (400X) throughout the metaphysis, starting approximately 0.25 mm distal from the growth and 10 
extending a further 0.5 mm. Osteoclast number measurements were quantified relative to total area (TA) present 11 
in each section, TA was divided by number of osteoclasts.  12 
Micro-computed Tomography (CT) analysis  13 
Three femurs from each time point and genotype were scanned using a Bruker microCT Skyscan™ CT 1072 14 
scanner (Kontich, Belgium) with an accelerated voltage of 50 kV and a current source of 197 uA at isotropic 15 
voxel size 5.1µm
3
. Measurements in the trabecular region were made in the distal metaphysis of the femur 16 
defined at 0.255mm under the growth plate extending 1mm (200 layers) toward to diaphysis, and excluding the 17 
outer cortical shell. Quantitative parameters were obtained by the Skyscan™ CT-analyzer software for the 18 
respective region of interest. The thickness of the cortical bone was measured in of 9 cross sections from the 19 
distal femoral metaphysis and diaphysis using the Dataviewer software (v1.4.4, Bruker, Belgium).  20 
Statistical analysis 21 
All statistical analyses were performed using Stata Statistical Software. The data was evaluated using one-way 22 
ANOVA followed by Bonferroni multiple comparisons test, with p˂0.05 considered statistically significant. 23 
Results are presented as means ± standard deviation (SD). 24 
Results  25 
T1DM reduces femur length and body weight in Ins2
Akita 
 26 
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Diabetes was confirmed by increased glucose concentrations observed at all time points in Ins2
Akita
 mice when 1 
compared to WT, with an increase of 271%, 306%, 356% at 4, 6 and 12 months respectively compared to age 2 
matched controls (figure 1). Diabetic mice also presented a significant decrease in femur length (figure 2.A) and 3 
lower body weight at all time points analyzed. Decrease in femur length were found to be of 5.4%, 5.3% and 4 
3.8%, at 4, 6, and 12 months respectively (figure 2.B), with highly significant statistical differences compared to 5 
controls (p<0.001). A significant decrease (p<0.05) of 27.1%, 26.2% and 26.9% was also observed in body 6 
weight of Ins2
Akita
 at 4, 6, and 12 months respectively (figure 2.C). 7 
Growth plate thickness is lower in Ins2
Akita 
 8 
Since potential alterations in growth plate structure are known to impair longitudinal bone growth, we 9 
investigated if the growth plate of Ins2
Akita
 could be affected. Growth plate measurements (Fig 3.A) showed that 10 
thickness was reduced in Ins2
Akita
 at 4 and 6 months, but at 12 months no significant differences could be 11 
observed compared to the WT counterparts (figure 3.B). Taking into account that bone lengthening depends on 12 
the proliferation of chondrocytes in the growth plate, we determined the total number of proliferative 13 
chondrocytes and found a significant reduction in this number at 4 and 6 months in Ins2
Akita
 compared to WT 14 
(figure 3.C). No differences were observed at 12 months, a result which is in agreement with growth plate 15 
thickness measurements. To determine if the number of hypertrophic chondrocytes was altered, we performed an 16 
immunohistochemical detection of caspase 3 with the objective of identifying pre-apoptotic cells (figure 4.A). 17 
The total number of chondrocytes in growth plate was determined by counting the cells under the microscope 18 
and significant differences were observed at 4 months, with the group of Ins2
Akita
  having a higher percentage of 19 
pre-apoptotic cells (figure 4.B).  20 
Ins2
Akita
 have lower cortical area and higher trabecular bone volume at 4, 6 at 12 months  21 
Total area (Tt.Ar) of cortical bone in the femur of Ins2
Akita
 was found to be reduced by 32% at 4 months, 16% at 22 
6 months and 25% at 12 months of age (Table 1 and figure 5.A). These differences were significant for all three 23 
age groups (p˂0.05) (Table 1). The reduction was mainly due to a substantial decrease in cortical area (Ct.Ar), of 24 
53% at 4 months, 35% at 6 months and 25% at 12 months, with all results being highly significant compared to 25 
WT controls (p<0.001) (Table 1 and Figure 5.B). This thinning of cortical bone observed in the diabetic mice 26 
was confirmed by a decrease in the cortical area fraction (Ct.Ar/Tt.Ar), cortical thickness (Ct.Th) and periosteal 27 
perimeter (Ps.Pm) (p<0.05) (Table 1). No significant differences were observed for the marrow area (Ma.Ar). A 28 
significant reduction could be found in the endocortical perimeter (Ec.Pm) (p<0.05) at 12 months (Table 1) but 29 
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not at 4 and 6 months. Diabetic mice did not show any signs of recovery or aggravation of the low cortical area 1 
with aging. Ct.Ar reduction was further confirmed by analyzing three different regions of the diaphysis of the 2 
tibia, (proximal, mid-shaft and distal) by histomorphometry (Figure 5.A). This analysis showed a significant 3 
reduction in Ins2
Akita
 Ct.Ar at all time points and regions (figure 5.C).  Trabecular bone parameters showed 4 
opposite results from those found in cortical bone (Figure 6.A). Differences in bone volume relative to trabecular 5 
volume (BV/TV) in Ins2
Akita 
were found to be highly significant at 4 months with an increase of 45% (p<0.001) 6 
at 4 months, of 46% (p<0.05) at 6 months and of 30% (p>0.05) at 12 months (Table 1 and Figure 6.B). 7 
Differences were also observed on the higher bone surface relative to trabecular volume (BS/TV) at 4 (p<0.001), 8 
6 (p<0.001) and 12 months (p<0.05). Higher BV/TV values in Ins2
Akita
 were due to a significant increase in the 9 
number of trabeculae (Tb.N), that was of 45% at 4 months (p<0.001), 52 % at 6 months (p<0.05) and 43% at 12 10 
months, and not due to the size of the trabeculae, since no differences were observed in the specific bone surface 11 
(BS/BV) or in the trabecular thickness (Tb.Th) (Table 1). In Ins2
Akita
 the high Tb.N led to a highly significant 12 
(p<0.001) reduction in trabecular separation (Tb.Sp) parameters in all 3 time points analyzed (Table 1). 13 
Histomorphometry of proximal mid-epiphysis of the tibia showed a significant increase of BV/TV in Ins2
Akita
 at 14 
all time points (figure 6.C), in agreement with results observed in the femur. Number of osteoclasts (ACP5 15 
positive cells) was found to be significantly reduced in Ins2
Akita
 mice at 4 and 6 months, suggesting reduced 16 
osteoclastogenesis and osteoclast activity (Figure 7.A and 7.B). 17 
Expression of cartilage and bone marker genes is altered in Ins2
Akita
  18 
To determine the mechanisms leading to alterations in the cartilage of Ins2
Akita
 we examined the expression 19 
levels of Adamst-5, which is involved in cleavage of proteoglycans, and Col2, the most abundant protein in 20 
cartilage. Adamst-5 was found to be overexpressed at all time points in Ins2
Akita
, being highly expressed at 4 and 21 
12 months (p<0.001) and also significantly upregulated at 6 months (p<0.05) (Figure 8.A). Col2 expression was 22 
found to be downregulated at both 4 and 6 months (p<0.05) compared to WT (Figure 8.B). Igf1 gene expression 23 
levels were found to be downregulated at 6 months (p<0.05) and strongly downregulated at 4 and 12 months 24 
(p<0.001) (Figure 8.C). Oc was found to be downregulated at 4 months (p<0.05) (Figure 8.D). Expression levels 25 
of Runx2 (Figure 8.E), the main transcription factor involved in osteoblast differentiation, were significantly 26 
downregulated at 4 and 6 months (p<0.05) in Ins2
Akita
 and finally the osteoclast marker Acp5 was also found to 27 
be significantly downregulated at 4 (p<0.01) and 6 months (p<0.05) (Figure 8.F). 28 
Serum concentrations of insulin and leptin is reduced in Ins2
Akita
  29 
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Blood serum concentrations of insulin and leptin was determined by ELISA and in both cases were found to be 1 
significantly reduced when compared to WT at 4, 6 and 12 months (p<0.001) (Figures 9.A and 9.B).    2 
 3 
Discussion 4 
T1DM has been associated to bone growth retardation in puberty (Donaghue, 2003) and increased risk of 5 
fracture throughout life, leading to higher morbidity and mortality (Weber, Haynes, Leonard, Willi, & Denburg, 6 
2015). Higher bone porosity and smaller cortical area are the principal causes for the observed decrease in 7 
biomechanical properties, as previously reported for type 2 diabetic postmenopausal women (Patsch et al., 8 
2013). In the present study, growth retardation could also be observed in the T1DM mice model Ins2
Akita
, 9 
reflected by a decrease in length of the femurs when compared to WT mice at all time points analyzed. Similar 10 
results were found in Ins2
Akita
 at 10 weeks (Coe et al., 2012) but also with other models like in streptozotocin 11 
induced diabetic mice and rats (Coe et al., 2012), in mice under caloric restriction (CR) (Devlin et al., 2010; 12 
Mark W Hamrick et al., 2008), and in ob/ob mice and in leptin receptor db/db mutant mice that showed altered 13 
osteoblastic activity and increased bone mass and volume (Ducy et al., 2000; Turner et al., 2013). This indicates 14 
that in mice models with altered glucose metabolism or altered energy metabolism there is an impairment of 15 
bone growth, either by dysregulation of direct signaling on osteoblasts by preventing insulin-receptor activation 16 
or by alterations in the control exerted by the central nervous system, as suggested in previous studies (Ducy et 17 
al. 2000; Lee et al. 2007; Ferron et al 2010).  18 
In this work, impaired bone growth can be explained by a reduction in growth plate thickness of Ins2
Akita
 mice at 19 
4 and 6 months and by a higher number of pre-apoptotic chondrocytes in growth plate at 4 months, reflecting a 20 
lower metabolic activity of the cartilage that translates into lower bone growth. Similar results were observed in 21 
diabetic rodents and in CR mice (Coe et al., 2012; Devlin et al., 2010), demonstrating a direct relation between 22 
early onset of diabetes and impairment of long bone growth. The reduction in growth plate thickness could also 23 
be explained by a decrease in the number of proliferative chondrocytes and by a downregulation of Col2, 24 
indicative of a decreased extracellular matrix production by chondrocytes, as also observed in Ins2
Akita
 at 10 25 
weeks (Coe et al., 2012). Increased inflammation in bone has been associated with osteoblast death related to 26 
bone marrow inflammatory events (Coe, Irwin, Lippner, & McCabe, 2011) particularly by increasing pro-27 
apoptotic and pro-inflammatory cytokines (K. J. Motyl & McCabe, 2009). An increase in tumor necrosis factor 28 
α (TNFα) is known to affect bone environment (Zhou et al. 2006) and has been associated with upregulation of 29 
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aggrecanase 5 (Adamst-5), a metalloproteinase exerting a potent effect on cartilage matrix degradation (Illien-1 
Junger et al., 2013). Accordingly, this enzyme was found to be highly expressed in our study, likely contributing 2 
to higher cartilage degradation. Our results showed low levels of Igf-1 expression in Ins2
Akita
 at all time points. 3 
Lower circulating Igf-1 concentrations have been associated with reduced linear growth (Yakar et al. 2002), 4 
higher cartilage degradation, and lower chondrocytic and osteoblastic proliferation (Kasukawa, Miyakoshi, & 5 
Mohan, 2004). Serum Igf-1 was also found to be lower in CR mice (Devlin et al., 2010; Mark W Hamrick et al., 6 
2008) caused by impaired growth hormone signaling (LeRoith & Yakar, 2007). These results suggest that a 7 
decrease in Igf-1 signaling might be involved in the reduction of bone quality parameters observed in our 8 
diabetic subjects.  9 
Diabetes has been associated to leptin deficiency (Motyl and McCabe 2009), and leptin treated mice were shown 10 
to have induced chondrocyte proliferation and enlarged growth plate thickness (Cornish et al., 2002; Turner et 11 
al., 2013) supporting our results that show a decreased leptin signaling in Ins2
Akita
 compared to WT mice 12 
observed at all time points analyzed after the onset of T1DM. In diabetes, intracellular glucose starvation mimics 13 
starvation periods and, not surprisingly, the results of growth retardation showed by Ins2
Akita
 resemble those 14 
found in CR mice. Our results on the microarchitecture of the distal femur, showing less cortical bone and more 15 
trabecular bone, also resemble the results observed in CR mice (Mark W Hamrick et al., 2008) as well as in 16 
Adrb2
-/-
 (Elefteriou et al., 2005) and ob/ob (Ducy et al., 2000) mice at 6 months. Moreover Adrb2
-/-
 mice at 4 17 
months (Pierroz et al., 2012) and ob/ob mice at 3 and 6 months (M. W. Hamrick, Pennington, Newton, Xie, & 18 
Isales, 2004; Turner et al., 2013) also showed a reduction of bone indexes in vertebrae. Lower insulin signaling 19 
in adipocytes and weight loss in diabetes leads to low expression of leptin (Martin & McCabe, 2007) and 20 
constitutes what Ins2
Akita
 may have in common with previous models that could explain these similarities is 21 
leptin deficiency. This results are similar to what was observed in this study with low levels of insulin detected 22 
in Ins2
Akita
 mice after the onset of disease and the reduction of insulin signaling can also explain the reduced 23 
levels of leptin observed at the same ages analyzed. To explain the mosaic phenotype, Hamrick et al. (2008) 24 
suggested that under caloric restriction there is a leptin deficiency and an increased neuropeptide Y signaling 25 
leading to reduced cortical bone. Baldock et al (2006) reported an increase in cortical bone volume in Y2 26 
receptor KO mice, but the mice double mutants for Y2 receptor and leptin showed a cortical bone volume 27 
similar to the presented by leptin mutant mice, meaning that cortical bone growth in leptin deficient mouse 28 
models cannot be explained only by this pathway. In the trabecular region, neither Coe et al. (2012), with 29 
Ins2
Akita
 mice at 10 weeks, nor Devlin et al. (2010) using CR mice at 12 weeks, found higher trabecular bone 30 
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volume, but instead there was a reduction of trabecular bone observed in those studies, probably due to the use of 1 
young adult specimens in which the phenotype in trabecular bone is still not established. These results are 2 
consistent with the fact that high trabecular bone volume could only be observed in Adrb2
-/-
 mice at 6 months 3 
and, more recently, at 4 months (Elefteriou et al., 2005; Pierroz et al., 2012). In our study we could detect this 4 
increase in trabecular bone in Ins2
Akita
 starting at 4 months. It was shown by Ducy et al. (2000) that ob/ob and 5 
db/db mutant mice at 6 months had higher trabecular BV/TV both in vertebrae and in tibia. To explain the high 6 
trabecular volume and low cortical bone volume, it has been shown that leptin have a neuroendocrine role 7 
increasing the expression of osteogenic markers related to bone formation, but also to stimulate bone resorption 8 
(Bartell et al., 2011; M. W. Hamrick et al., 2004) or by suggesting a higher significance of the stimulatory effect 9 
of leptin in bone peripherally. Turner et al. ( 2013) have proposed that leptin can influence bone by acting 10 
centrally and peripherally, and in both cases leptin induces bone formation and resorption, concluding that 11 
regulation was predominantly made by direct signaling on both the osteoblastic and osteoclastic lineages.  12 
Lower Oc and even lower cross-linked C-telopeptide serum levels in leptin mutant ob/ob and in the leptin 13 
receptor mutant db/db mice was associated with low bone formation and low bone resorption (Turner et al., 14 
2013). These conclusions led to the assumption that higher bone volume in the trabecular bone of the vertebrae 15 
was due to lower bone formation but an even higher reduction in bone resorption. Turner and collaborators 16 
(2013) proposed an interesting model to explain the lower cortical bone and higher trabecular bone phenotype. 17 
Since leptin acts over chondrocytes, osteoblasts and osteoclasts, to enhance their number and/activity, changes in 18 
bone mass and architecture are dependent on local prevalence of osteoblasts and osteoclasts. So, in the 19 
periosteum of the cortical bone, where we have a higher presence of osteoblasts and lower numbers of 20 
osteoclasts, it is expected a lower bone formation in leptin deficient models. In trabecular bone, reduction in 21 
bone resorption can preserve trabecular number, providing a scaffold for addition of new bone. This theory is in 22 
agreement with our results, since trabecular bone surface (BS/TV) and trabecular number (Tb.N) in Ins2
Akita
 were 23 
always significantly higher, the number of osteoclasts and Acp5 expression was reduced at 4 and 6 months while 24 
the expression of genes associated with bone formation (Oc and Runx2) showed to be downregulated, 25 
particularly at 4 months, when we could detect higher histomorphometric differences in trabecular and cortical 26 
bone. It has also been shown by Kalra et al. (2009) that 10 weeks old Akita mice had significantly lower plasma 27 
Oc than WT mice, confirming a lower osteoblastic activity. Other explanation for the presumable lower bone 28 
formation and resorption rate expressed by our results, is the fact that insulin signaling in osteoblasts has been 29 
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associated to higher osteoblast and osteoclast activity promoting both bone formation and resorption (Lee et al., 1 
2007).  2 
Fulzele et al. (2010) working with mice lacking insulin receptor in osteoblasts, Ob-IR, could observe a reduction 3 
in number of osteoblasts, bone formation rate and serum CTx. Although presenting signs of lower bone 4 
formation and resorption, Ob-IR showed lower BV/TV and Tb.N in the trabecular region at 3 and 6 weeks. But 5 
at 3 months, Ob-IR presented only a trend of lower BV/TV and Tb.N, leading us to question what would be the 6 
trabecular phenotype of older Ob-IR mice. In addition, Motyl et al. (2009) and Motyl and McCabe (2009) 7 
observed a lower relative expression of Acp5 mRNA in induced diabetic type 1 mice, suggesting lower bone 8 
resorption, and a downregulation of osteogenic genes Runx2 and Oc.  9 
Hyperglycemia has been associated to lower bone quality, especially by the role of AGEs that have been shown 10 
to reduce osteoblastic differentiation and by increasing osteoclast bone resorption. These findings are supported 11 
by work with KO mice for the receptor for AGEs (RAGE), that presented higher bone volume and lower bone 12 
resorption (Zhou et al. 2006). Although the possible higher signaling of AGEs in osteoblasts resembles the lower 13 
bone volume observed in our study, osteoclast activation by RAGE conflicts with our data and with the majority 14 
of reports with type 1 diabetic models (Motyl and McCabe 2009; Motyl et al. 2009) that suggests lower bone 15 
resorption. Nevertheless, AGEs are thought to be preponderant in reducing the biomechanical properties of bone, 16 
since they accumulate in bone matrix, reducing bone strength and increasing fracture risk (Yamamoto, 17 
Yamaguchi, Yamauchi, Yano, & Sugimoto, 2008).  18 
High bone marrow adiposity has been associated to reduced bone formation (Devlin et al., 2010), due to the fact 19 
that adipogenesis and osteoblastogenesis are derived from a common mesenchymal precursor and selection of 20 
adipose lineage could lead to reduced number of osteoblasts although this hypothesis as not yet been confirmed 21 
(Motyl and McCabe 2009). It has been proposed that marrow adipose tissue may act physiologically to provide 22 
an expandable/contractible fat depot for sustaining optimal hematopoiesis (Turner, Martin, & Iwaniec, 2018). 23 
Also inflammation in bone environment has been pointed as a possible cause for reduced bone formation, when 24 
the MC3T3 osteoblastic cell line was exposed to bone marrow from diabetic mice it resulted in increased 25 
osteoblast death, but when co-cultured with TNFα neutralizing antibodies the cell death response was reduced 26 
(Coe et al., 2011). 27 
Reduced bone formation in Type 1 diabetes mellitus seems to have multifactorial explanations, but reduced bone 28 
resorption can be explained, in part, by the reduced insulin and leptin signaling in osteoblasts and/or osteoclasts, 29 
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as previously reported. Like in previous reports (Jun, Ma, Pyla, & Segar, 2012; Naito et al., 2011; Schoeller et 1 
al., 2014),  Ins2
Akita 
in our study showed to be insulin and leptin deficient, and this double disorder may explain 2 
why diabetic mutants presented such marked differences, where in the trabecular region of the Ins2
Akita 
at 4 3 
months bone volume was almost two times higher. Although Motyl and McCabe (2009) have tried to reverse 4 
bone alterations observed in Ins2
Akita
 mice using leptin treatments, it proved unsuccessful.  5 
Future studies should focus in understanding the molecular roles of leptin in Type 1 diabetes mellitus and also to 6 
evaluate treatments at different life stages or during longer periods of treatment. Finally, we have for the first 7 
time identified a clear effect of diabetes in the microarchitecture of the long bones in the T1DM model Ins2
Akita
 8 
and we concluded that the high trabecular bone volume can be explained by altered bone remodeling caused by 9 
lack of insulin signaling and leptin deficiency, or both acting synergistically. 10 
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Figure Legends 1 
Figure 1. Higher glucose concentrations in Ins2
Akita
. Blood glucose concentration is higher in Ins2
Akita
 at all 2 
time points compared to WT. 5 animals per group and time point were evaluated. *p<0.05, **p<0.001. Error 3 
bars represent SD. 4 
Figure 2. Ins2
Akita
 presents shorter femurs. A. X-ray analysis of Ins2
Akita
 and WT mice femurs at 4, 6 and 12 5 
months; B. Ins2Akita  femur length is  significantly smaller than WT at 4, 6 and 12 months, demonstrating that 6 
type 1 diabetes mellitus is related to growth retardation. C. Body weight of Ins2
Akita
 is significantly lower 7 
compared to WT at 4, 6 and 12 months. 5 animals per group and time point were evaluated. *p<0.05, **p<0.001. 8 
Error bars represent SD. 9 
Figure 3. Reduced growth plate thickness in Ins2
Akita
. A. Growth plate thickness of Ins2
Akita 
mice and WT. A 10 
lower number of proliferative chondrocytes led to thinner growth plates and to decreased longitudinal bone 11 
growth; black arrows represent measurements of growth plate thickness of WT; B. and C. growth plate thickness 12 
and number of proliferative chondrocytes are significantly lower at 4 and 6 months in Ins2
Akita
 but not at 12 13 
months. 5 animals per group and time point were evaluated. *p<0.05. Error bars represent SD. 14 
Figure 4. Increased apoptosis in Ins2
Akita
 growth plate. A. Evaluation of pre-apoptotic cells by 15 
immunohistochemistry in growth plate (black and yellow arrows: caspase 3 positive and negative cells, 16 
respectively); B. Ins2
Akita 
showed a significant increase in number of pre-apoptotic chondrocytes in the growth 17 
plate compared to WT. 3 animals per group were evaluated. *p<0.05. Error bars represent SD. 18 
Figure 5. Reduced cortical area in long bones of Ins2
Akita. A. Histological sections of the cortical proximal, 19 
mid-shaft and distal regions of the tibia and microCT images of the cortical diaphyseal distal shaft of the femur 20 
of Ins2
Akita 
and WT mice of 4, 6 and 12 months. Diabetes induced cortical bone loss and significant differences 21 
could be found in Tt.Ar, Ct.Ar, Ct.Ar/Tt.Ar, Ct.Th, Ps.Pm. Bone volume reduction occurred by the decline in 22 
periosteum perimeter suggesting lower bone formation; B.  Ins2
Akita 
mice have significantly lower proximal, mid-23 
shaft and distal cortical bone area of the tibia when compared to WT mice at 4, 6 and 12 months assessed by 24 
histomorphometry analysis; C. Ins2
Akita 
mice have significantly lower cortical bone area of the femur when 25 
compared to WT mice at 4, 6 and 12 months, assessed by microCT analysis. 3 animals per group and time point 26 
were used for microCT analysis and 5 for histomorphometry evaluation. *p<0.05, **p<0.001. Error bars 27 
represent SD. 28 
Figure 6. Increased trabecular bone volume in Ins2
Akita
. A. Histological sections of the proximal mid-29 
epiphysis of the tibia and microCT images of the distal mid-epiphysis of femur of Ins2
Akita
 and WT mice of 4, 6 30 
and 12 months. Significant differences could be seen in BV/TV, BS/TV, Tb.N and Tb.Sp bone parameters. The 31 
higher bone volume observed in Ins2Akita trabeculae is explained by the increase in trabeculae number and not 32 
trabeculae thickness or size. These results also suggest lower bone resorption; B. Ins2
Akita
 mice showed a 33 
significant increase in trabecular bone volume (BV/TV) of the femur when compared to WT mice at 4, 6 months 34 
by microCT analysis; C. Ins2
Akita
 mice showed a significant increase in trabecular bone volume (BV/TV) of the 35 
tibia when compared to WT mice at 4, 6 and 12 months by histomorphometric analysis. 3 animals per group and 36 
time point were used for microCT analysis and 5 for histomorphometry evaluation. *p<0.05, **p<0.001. Error 37 
bars represent SD. 38 
Figure 7. ACP5 positive cells are reduced in Ins2
Akita
. A. Undecalcified histological sections of  proximal mid-39 
epiphysis of the femur of Ins2
Akita
 and WT mice of 4, 6 and 12 months were used for osteoclasts identification by 40 
ACP5positive cells; B. ACP5 positive cells were lower in Ins2
Akita
 when compared to WT. 5 animals per group 41 
and time point were evaluated. *p<0.05, **p<0.001. Error bars represent SD. 42 
Figure 8. Altered expression of bone markers in Ins2
Akita
. Diabetes in Ins2
Akita
 induced changes in mRNA 43 




suggesting higher 44 
cartilage degradation; B. Col2 expression is reduced at 4 and 6 months in Ins2
Akita  
in accordance with the lower 45 
cartilage matrix area of growth plate; C. Igf1 expression is lower at all ages in Ins2
Akita
; D. Oc is downregulated 46 
at 4 months in Ins2Akita; E. Runx2 was downregulated at 4 and 6 months in Ins2Akita, suggesting lower bone 47 
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growth. F. Acp5 was found to be downregulated at 4 and 6 months in Ins2
Akita
. *p<0.05, **p<0.001. RNA from 5 1 
animals were evaluated per group and time point. Error bars represent SD. 2 
Figure 9. Blood serum concentrations of insulin and leptin are reduced in Ins2
Akita
 mice. Serum 3 
concentrations were reduced at 4, 6 and 12 months in Ins2Akita mice when compared to WT. *p<0.001. Error 4 
bars represent SD. 5 




Figure 1. Higher glucose concentrations in Ins2Akita. Blood glucose concentration is higher in Ins2Akita at all 
time points compared to WT. 5 animals per group and time point were evaluated. *p<0.05, **p<0.001.  
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Caption : Figure 2. Ins2Akita presents shorter femurs. A. X-ray analysis of Ins2Akita and WT mice femurs at 4, 
6 and 12 months; B. Ins2Akita femur length is significantly smaller than WT at 4, 6 and 12 months, 
demonstrating that type 1 diabetes mellitus is related to growth retardation. C. Body weight of Ins2Akita is 
significantly lower compared to WT at 4, 6 and 12 months. 5 animals per group and time point were 
evaluated. *p<0.05, **p<0.001.  
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Figure 3. Reduced growth plate thickness in Ins2Akita. A. Growth plate thickness of Ins2Akita mice and WT. A 
lower number of proliferative chondrocytes led to thinner growth plates and to decreased longitudinal bone 
growth; black arrows represent measurements of growth plate thickness of WT; B. and C. growth plate 
thickness and number of proliferative chondrocytes are significantly lower at 4 and 6 months in Ins2Akita but 
not at 12 months. 5 animals per group and time point were evaluated. *p<0.05.  
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Figure 4. Increased apoptosis in Ins2Akita growth plate. A. Evaluation of pre-apoptotic cells by 
immunohistochemistry in growth plate (black and yellow arrows: caspase 3 positive and negative cells, 
respectively); B. Ins2Akita showed a significant increase in number of pre-apoptotic chondrocytes in the 
growth plate compared to WT. 3 animals per group were evaluated. *p<0.05  
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Figure 5. Reduced cortical area in long bones of Ins2Akita. A. Histological sections of the cortical proximal, 
mid-shaft and distal regions of the tibia and microCT images of the cortical diaphyseal distal shaft of the 
femur of Ins2Akita and WT mice of 4, 6 and 12 months. Diabetes induced cortical bone loss and significant 
differences could be found in Tt.Ar, Ct.Ar, Ct.Ar/Tt.Ar, Ct.Th, Ps.Pm. Bone volume reduction occurred by the 
decline in periosteum perimeter suggesting lower bone formation; B. Ins2Akita mice have significantly lower 
proximal, mid-shaft and distal cortical bone area of the tibia when compared to WT mice at 4, 6 and 12 
months assessed by histomorphometry analysis; C. Ins2Akita mice have significantly lower cortical bone area 
of the femur when compared to WT mice at 4, 6 and 12 months, assessed by microCT analysis. 3 animals 
per group and time point were used for microCT analysis and 5 for histomorphometry evaluation. *p<0.05,  
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Figure 6. Increased trabecular bone volume in Ins2Akita. A. Histological sections of the proximal mid-
epiphysis of the tibia and microCT images of the distal mid-epiphysis of femur of Ins2Akita and WT mice of 4, 
6 and 12 months. Significant differences could be seen in BV/TV, BS/TV, Tb.N and Tb.Sp bone parameters. 
The higher bone volume observed in Ins2Akita trabeculae is explained by the increase in trabeculae number 
and not trabeculae thickness or size. These results also suggest lower bone resorption; B. Ins2Akita mice 
showed a significant increase in trabecular bone volume (BV/TV) of the femur when compared to WT mice at 
4, 6 months by microCT analysis; C. Ins2Akita mice showed a significant increase in trabecular bone volume 
(BV/TV) of the tibia when compared to WT mice at 4, 6 and 12 months by histomorphometric analysis. 3 
animals per group and time point were used for microCT analysis and 5 for histomorphometry evaluation. 
*p<0.05, **p<0.001.  
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Figure 7. ACP5 positive cells are reduced in Ins2Akita. A. Undecalcified histological sections of proximal mid-
epiphysis of the femur of Ins2Akita and WT mice of 4, 6 and 12 months were used for osteoclasts 
identification by ACP5positive cells; B. ACP5 positive cells were lower in Ins2Akita when compared to WT. 5 
animals per group and time point were evaluated. *p<0.05, **p<0.001.  
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Figure 8. Altered expression of bone markers in Ins2Akita. Diabetes in Ins2Akita induced changes in mRNA gene 
expression in cartilage and bone; A. Adamst-5 expression is higher at all ages in Ins2Akita suggesting higher 
cartilage degradation; B. Col2 expression is reduced at 4 and 6 months in Ins2Akita in accordance with the 
lower cartilage matrix area of growth plate; C. Igf1 expression is lower at all ages in Ins2Akita; D. Oc is 
downregulated at 4 months in Ins2Akita; E. Runx2 were downregulated at 4 and 6 months in Ins2Akita, 
suggesting lower bone growth. F. Acp5 was found to be downregulated at 4 and 6 months in Ins2Akita. 
*p<0.05, **p<0.001. RNA from 5 animals were evaluated per group and time point.  
 
151x158mm (300 x 300 DPI)  
 
 




Figure 9. Blood serum concentrations of insulin and leptin are reduced in Ins2Akita mice. Serum 
concentrations were reduced at 4, 6 and 12 months in Ins2Akita mice when compared to WT. *p<0.001.  
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